Share on Pinterest UCLA researchers recently found that PSA levels after prostate cancer treatment may not be the best indicator of survival. andresr/Getty Images A new study from UCLA researchers ...
A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...
Men with metastatic hormone-sensitive prostate cancer treated with Nubeqa, androgen-deprivation therapy and docetaxel had reductions in PSA levels that were associated with improved overall survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results